RBC Capital Reinstates Alexion Pharmaceuticals (ALXN) at Outperform
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reinstates coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with an Outperform rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
